tiprankstipranks
Valneva Highlights Chikungunya’s Global Economic Impact
Company Announcements

Valneva Highlights Chikungunya’s Global Economic Impact

Valneva (VALN) has released an update.

Pick the best stocks and maximize your portfolio:

Valneva SE has published a study in The British Medical Journal highlighting the severe health and economic impacts of chikungunya, a mosquito-borne disease. The study reveals that between 2011 and 2020, chikungunya caused significant health challenges and an estimated $49.9 billion in economic costs globally. This underscores the need for effective control strategies as the disease continues to spread, exacerbated by climate change.

For further insights into VALN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskValneva’s Chikungunya Vaccine Shows Long-Lasting Efficacy
TipRanks Auto-Generated NewsdeskValneva Seeks FDA Approval for Expanded Vaccine Use
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App